Johnson & Johnson announced Tuesday that a booster dose of its single-shot COVID-19 substantially boosted protection against symptomatic illness in clinical trials.

A second dose of the vaccine administered about two months after the first was 94% successful at preventing symptomatic illness caused by the virus and substantially increased the vaccine’s effectiveness at preventing severe infection resulting in hospitalization or death.